U.S. Latent Tuberculosis Infection Detection Market (2026 - 2033) Size, Share & Trends Analysis Report By Test (IGRA, TST), By Application (Household Contacts With Pulmonary TB, PLHIV), By End-use (Diagnostic Laboratories, Hospitals/Clinics), By Region, And Segment Forecasts

Table of Contents

Chapter 1. Methodology and Scope
                    1.1. Market Segmentation and Scope
                    1.2. Segment Definitions
                        1.2.1. Test
                        1.2.2. Application
                        1.2.3. End Use
                        1.2.4. Estimates and forecasts timeline
                    1.3. Objectives
                        1.3.1. Objective-1
                        1.3.2. Objective-2
                        1.3.3. Objective-3
                    1.4. Research Methodology
                    1.5. Information Procurement
                        1.5.1. Purchased database
                        1.5.2. GVR’s internal database
                        1.5.3. Secondary sources
                        1.5.4. Primary research
                    1.6. Information or Data Analysis
                        1.6.1. Data analysis models
                    1.7. Market Formulation & Validation
                    1.8. Model Details
                        1.8.1. Commodity flow analysis
                            1.8.1.1. Approach 1: Commodity flow approach
                            1.8.1.2. Approach 2: Country-wise market estimation using bottom-up approach
                    1.9. List of Secondary Sources
                    1.10. List of Primary Sources
                    1.11. Objectives
Chapter 2. Executive Summary
                    2.1. Market Outlook
                    2.2. Test Snapshot
                    2.3. Application and End-use Snapshot
                    2.4. Competitive Insights
Chapter 3. U.S. Latent Tuberculosis Infection Detection Market Variables, Trends & Scope
                    3.1. Market Lineage Outlook
                        3.1.1. Parent Market Outlook (Latent Tuberculosis Infection Detection Market)
                        3.1.2. Related/ancillary market outlook (Tuberculosis Diagnostics Market)
                    3.2. Market Dynamics
                        3.2.1. Market Driver Analysis
                            3.2.1.1. Increase in risk of developing active Tuberculosis Infection from LTBI
                            3.2.1.2. Increasing Funding Programs to Promote TB Diagnostics
                            3.2.1.3. Technological Advancements in Diagnostics Methods
                        3.2.2. Market Restraint Analysis
                            3.2.2.1. Limited Awareness and Underdiagnosis of Latent TB
                        3.2.3. Market Opportunity Analysis
                            3.2.3.1. Growing Focus on TB Elimination and Preventive Care
                            3.2.3.2. Expansion of Community-Based and Targeted Screening Programs
                        3.2.4. Market Challenge Analysis
                            3.2.4.1. Low Disease Visibility and Competing Public Health Priorities
                     3.3. U.S. Latent Tuberculosis Infection Detection Market Analysis Tools
                        3.3.1. Industry Analysis - Porter’s
                            3.3.1.1. Bargaining power of suppliers
                            3.3.1.2. Bargaining power of buyers
                            3.3.1.3. Threat of substitutes
                            3.3.1.4. Threat of new entrants
                            3.3.1.5. Competitive rivalry
                        3.3.2. PESTEL Analysis
                            3.3.2.1. Political landscape
                            3.3.2.2. Economic landscape
                            3.3.2.3. Social landscape
                            3.3.2.4. Technological landscape
                            3.3.2.5. Environmental landscape
                            3.3.2.6. Legal landscape
                    3.4. Regulatory Framework
                    3.5. Reimbursement Scenario
                    3.6. Payment/ Reimbursement for Immigration Testing
                    3.7. CLIA Labs in the U.S.
                        3.7.1. List of all the CLIA Labs in the U.S
                        3.7.2. List of CLIA and NYS Certified Labs that Perform QFT (CPT 86480), T-SPOT.TB (86481), TST (86580), and their Volumes
                        3.7.3. List of Physicians and Volumes Ordered of the Tests Split out by NPI, Geography, and Practice
Chapter 4. U.S. Latent Tuberculosis Infection Detection Market: Test Estimates & Trend Analysis
                    4.1. Segment Dashboard
                    4.2. U.S. Latent Tuberculosis Infection Detection Market: Test Movement Analysis
                    4.3. U.S. Latent Tuberculosis Infection Detection Market by Test Outlook (USD Million)
                    4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033, for the following
                    4.5. Interferon Gamma Released Assay (IGRA)
                        4.5.1. Interferon Gamma Released Assay (IGRA) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
                        4.5.2. Interferon Gamma Released Assay (IGRA) Market Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)
                        4.5.3. QFT
                            4.5.3.1. QFT Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
                            4.5.3.2. QFT Market Revenue Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)
                        4.5.4. T. SPOT
                            4.5.4.1. T. SPOT Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
                            4.5.4.2. T. SPOT Market Revenue Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)
                    4.6. Tuberculin Skin Test (TST)
                        4.6.1. Tuberculin Skin Test (TST) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
                        4.6.2. Tuberculin Skin Test (TST) Market Revenue Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)
Chapter 5. U.S. Latent Tuberculosis Infection Detection Market: Application Estimates & Trend Analysis
                    5.1. Segment Dashboard
                    5.2. U.S. Latent Tuberculosis Infection Detection Market: Application Movement Analysis
                    5.3. U.S. Latent Tuberculosis Infection Detection Market by Application Outlook (USD Million)
                    5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033, for the following
                    5.5. Household Contacts With Pulmonary TB
                        5.5.1. Household Contacts With Pulmonary TB Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
                        5.5.2. Household Contacts With Pulmonary TB Market Revenue Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)
                    5.6. PLHIV
                        5.6.1. PLHIV Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
                        5.6.2. PLHIV Market Revenue Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)
                    5.7. Others
                        5.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
                        5.7.2. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)
Chapter 6. U.S. Latent Tuberculosis Infection Detection Market: End Use Estimates & Trend Analysis
                    6.1. Segment Dashboard
                    6.2. U.S. Latent Tuberculosis Infection Detection Market: End Use Movement Analysis
                    6.3. U.S. Latent Tuberculosis Infection Detection Market by End Use Outlook (USD Million)
                    6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033, for the following
                    6.5. Diagnostic Laboratories
                        6.5.1. Diagnostic Laboratories Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
                        6.5.2. Diagnostic Laboratories Market Revenue Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)
                    6.6. Hospitals/Clinics
                        6.6.1. Hospitals/Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
                        6.6.2. Hospitals/Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)
                    6.7. Academic & Research Institutions
                        6.7.1. Academic & Research Institutions Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
                        6.7.2. Academic & Research Institutions Market Revenue Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)
Chapter 7. Competitive Landscape
                    7.1. Market Participant Categorization
                    7.2. Recent Developments & Impact Analysis by Key Market Participants
                    7.3. Company Market Share Analysis, 2025
                    7.4. Key Company Profiles
                        7.4.1. QIAGEN
                            7.4.1.1. Company overview
                            7.4.1.2. Financial performance
                            7.4.1.3. Product benchmarking
                            7.4.1.4. Strategic initiatives
                        7.4.2. Euroimmun US
                            7.4.2.1. Company overview
                            7.4.2.2. Financial performance
                            7.4.2.3. Product benchmarking
                            7.4.2.4. Strategic initiatives
                        7.4.3. bioMérieux
                            7.4.3.1. Company overview
                            7.4.3.2. Financial performance
                            7.4.3.3. Product benchmarking
                            7.4.3.4. Strategic initiatives
                        7.4.4. Oxford Immunotec
                            7.4.4.1. Company overview
                            7.4.4.2. Financial performance
                            7.4.4.3. Product benchmarking
                            7.4.4.4. Strategic initiatives
                        7.4.5. SD Biosensor, INC.
                            7.4.5.1. Company overview
                            7.4.5.2. Financial performance
                            7.4.5.3. Product benchmarking
                            7.4.5.4. Strategic initiatives
                        7.4.6. Quest Diagnostics
                            7.4.6.1. Company overview
                            7.4.6.2. Financial performance
                            7.4.6.3. Product benchmarking
                            7.4.6.4. Strategic initiatives
                        7.4.7. LabCorp
                            7.4.7.1. Company overview
                            7.4.7.2. Financial performance
                            7.4.7.3. Product benchmarking
                            7.4.7.4. Strategic initiatives
                        7.4.8. ARUP Laboratories
                            7.4.8.1. Company overview
                            7.4.8.2. Financial performance
                            7.4.8.3. Product benchmarking
                            7.4.8.4. Strategic initiatives
                        7.4.9. Mayo Clinic Laboratories
                            7.4.9.1. Company overview
                            7.4.9.2. Financial performance
                            7.4.9.3. Product benchmarking
                            7.4.9.4. Strategic initiatives
                        7.4.10. BioReference Laboratories
                            7.4.10.1. Company overview
                            7.4.10.2. Financial performance
                            7.4.10.3. Product benchmarking
                            7.4.10.4. Strategic initiatives
                        7.4.11. Par Pharmaceutical, Inc.
                            7.4.11.1. Company overview
                            7.4.11.2. Financial performance
                            7.4.11.3. Product benchmarking
                            7.4.11.4. Strategic initiatives

List of Tables

Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 List of all the CLIA labs in the U.S
Table 4 List of CLIA and NYS certified labs that perform QFT (CPT 86480), T-SPOT.TB (86481), TST (86580), and their volumes
Table 5 List of physicians and volumes ordered of the tests, split out by NPI, geography, and practice
Table 6 U.S. latent tuberculosis infection detection market, by test, 2021 - 2033 (USD Million)
Table 7 U.S. latent tuberculosis infection detection market, by application, 2021 - 2033 (USD Million)
Table 8 U.S. latent tuberculosis infection detection market, by end use, 2021 - 2033 (USD Million)

List of Figures

Fig. 1 U.S. latent tuberculosis infection detection market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value chain-based sizing & forecasting
Fig. 7 QFD modelling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 U.S. latent tuberculosis infection detection market snapshot
Fig. 10 Test snapshot
Fig. 11 Application and end-use snapshot
Fig. 12 Competitive landscape snapshot
Fig. 13 Parent market outlook
Fig. 14 Related/ancillary market outlook
Fig. 15 Market dynamics
Fig. 16 Market driver analysis (current & future impact)
Fig. 17 Market restraint analysis (current & future impact)
Fig. 18 Porter’s five forces analysis
Fig. 19 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 20 U.S. latent tuberculosis infection detection market, test outlook key takeaways
Fig. 21 U.S. latent tuberculosis infection detection market, test movement analysis
Fig. 22 IGRA market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 23 IGRA market revenue estimates and forecasts, 2021 - 2033 (Number of Tests in Thousands)
Fig. 24 Tuberculin Skin Test (TST) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 25 Tuberculin Skin Test (TST) market revenue estimates and forecasts, 2021 - 2033 (Number of Tests in Thousands)
Fig. 26 QFT market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 27 QFT market revenue estimates and forecasts, 2021 - 2033 (Number of Tests in Thousands)
Fig. 28 T.SPOT market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 29 T.SPOT market revenue estimates and forecasts, 2021 - 2033 (Number of Tests in Thousands)
Fig. 30 U.S. latent tuberculosis infection detection market, application outlook key takeaways
Fig. 31 U.S. latent tuberculosis infection detection market, application movement analysis
Fig. 32 Household Contacts with Pulmonary TB market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 33 Household Contacts with Pulmonary TB market revenue estimates and forecasts, 2021 - 2033 (Number of Tests in Thousands)
Fig. 34 PLHIV market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 35 PLHIV market revenue estimates and forecasts, 2021 - 2033 (Number of Tests in Thousands)
Fig. 36 Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 37 Others market revenue estimates and forecasts, 2021 - 2033 (Number of Tests in Thousands)
Fig. 38 U.S. latent tuberculosis infection detection market, end use outlook key takeaways
Fig. 39 U.S. latent tuberculosis infection detection market, end use movement analysis
Fig. 40 Diagnostic Laboratories market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 41 Diagnostic Laboratories market revenue estimates and forecasts, 2021 - 2033 (Number of Tests in Thousands)
Fig. 42 Hospitals/Clinics market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 43 Hospitals/Clinics market revenue estimates and forecasts, 2021 - 2033 (Number of Tests in Thousands)
Fig. 44 Academic & Research Institutions market revenue estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 45 Academic & Research Institutions market revenue estimates and forecasts, 2021 - 2033 (Number of Tests in Thousands)
Fig. 46 Key company categorization
Fig. 47 Strategy mapping